Qiming Venture Partners' portfolio company CanSino Biologics Inc. (“CanSinoBIO”) (SEHK:6185, SHSE:688185) announced that the National Medical Products Administration of China (“NMPA”) has granted the Company approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) to be used as a booster dose.
Utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia™, Convidecia Air™ provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air™ is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
CanSinoBIO received the approval of its clinical trial application for Convidecia Air™ in March 2021. Studies published in The Lancet indicated that Convidecia Air™ can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.
Currently, CanSinoBIO has achieved steady production of various innovative vaccines and established a global supply chain, with a goal to continue to make quality vaccine products more accessible by the global population.
